The major aim of the DF&DDS Research Group is formulation of the conventional and modified-release dosage forms (DF). Special attention is paid to development and testing of micro- and nanoparticle carrier drug delivery systems (DDS), mainly for antineoplastic and nonsteroidal anti-inflammatory drugs. The group also deals with improvement solubility/bioavailability of BCS II/IV drugs using specific technological procedures such as liquisolid systems, self-emulsifying systems or co/milling with specific carriers.
Improvement in API solubility & release
|
![Vystrizek_solubilization.JPG Vystrizek_solubilization.JPG](/getattachment/Groups/Drug-Delivery-Dosage-Form-Technology/Vystrizek_solubilization.JPG.aspx?width=700&height=340) |
3D printing
|
![Vystrizek_3D-printing.JPG Vystrizek_3D-printing.JPG](/getattachment/Groups/Drug-Delivery-Dosage-Form-Technology/Vystrizek_3D-printing.JPG.aspx?width=700&height=375) |
Mesoporous silica-based systems
|
![Vystrizek-mesoporous-silica-based-systems.JPG Vystrizek-mesoporous-silica-based-systems.JPG](/getattachment/Groups/Drug-Delivery-Dosage-Form-Technology/Vystrizek-mesoporous-silica-based-systems.JPG.aspx?width=700&height=303) |
PLGA drug delivery systems
|
![Vystrizek_PLGA-based-DDS.JPG Vystrizek_PLGA-based-DDS.JPG](/getattachment/Groups/Drug-Delivery-Dosage-Form-Technology/Vystrizek_PLGA-based-DDS.JPG.aspx?width=700&height=312) |